Pharmacologic modulation of fetal hemoglobin

Medicine

Volumn 80, Issue 5, 2001, Pages 328-344

  Steinberg, Martin H ^a,c   Rodgers, Griffin P ^b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; BUTYRIC ACID; CYTOKINE; DROXIA; ERYTHROPOIETIN; HEMOGLOBIN F; HEMOGLOBIN S; HISTONE DEACETYLASE; HYDROXYUREA; SHORT CHAIN FATTY ACID; T LYMPHOCYTE RECEPTOR;

ACUTE LEUKEMIA; BETA THALASSEMIA; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; ERYTHROID CELL; GENE EXPRESSION; GENE LOCUS; HEMOGLOBIN SYNTHESIS; HUMAN; PRIORITY JOURNAL; REVIEW; SICKLE CELL ANEMIA; TREATMENT INDICATION;

ANEMIA, SICKLE CELL; ANTISICKLING AGENTS; BETA-THALASSEMIA; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; ERYTHROCYTES; FETAL HEMOGLOBIN; GENE EXPRESSION REGULATION; HUMANS; HYDROXYUREA; INFANT; INFANT, NEWBORN;

EID: 0034820416     PISSN: 00257974     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005792-200109000-00007     Document Type: Review

References (178)

1. Hydroxyurea in sickle cell disease
2. A pilot trial of hydroxyurea to prevent strokes in children with sickle cell anemia
3. Uydroxyurea affects cell morphology cation transport and red blood cee adhesion in cultured vascular endothelial cells
4. Cooperative enhancement of F-cell formation in baboons treated with erythropoietin and hydroxyurea
5. Erythropoietin stimulates F-reticulocyte formation in sickle cell anemia
6. FKLF-2: A novel Kluppel-like transcriptional factor that activates globin and other erythoroid lineage genes
7. Sustained induction of fetal hemoglobin by pulse butyrate therapy in sickle cell disease
8. Effect of hydroxyurea on the rheological properties of sickle erythroclaes in vivo
9. Erythropoietic activity in patients with sickle cell anaemia before and after treatment with hydroxyurea
10. Secondary leukemia following hydroxyurea in patients with essential thrombocythemia: Long-term results of a randomized clinical trial
11. Clinical management of gene expression
12. Hydroxyurea-induced leg ulceration in 14 patients
13. Effect of methemoglobin formation in sickle cell disease
14. A mammalian protein with specific demethylase activity for mCpG DNA
15. Fetal hemoglobin in acute and chronic states of erythroid expansion
16. Fetal hemoglobin induction with butyric acid: Efficacy and toxicity
17. Regulation of fetal hemoglobin
18. Selectively increased growth of fetal hemoglobin-expressing adult erythroid progenitors after brief treatment of early progenitors with transforming growth factor beta
19. Short-chain fatty acid derivatives stimulate cell proliferation and induce STAT-5 activation
20. Fetal hemoglobin restriction to a few erythroclaes (F cells) in normal human adults
21. A multiparameter analysis of sickle erythrocytes in patients undergoing hydroxyurea therapy
22. Thrombospondin from activated platelets promotes sickle erythrocyte adherence to human microvascular endothelium under physiologic flow: A potential role for platelet activation in sickle cell vaso-occlusion
23. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent
24. Treatment of sickle cell anemia with 5-azacytidine results in increased fetal hemoglobin production and is associated with nonrandom hypomethylation of DNA around the γ-δ-β globin gene complex
25. Hydroxyurea: Effects on hemoglobin F production in patients with sickle cell anemia
26. Hydroxyurea-induced augmentation of fetal hemoglobin production in patients with sickle cell anemia
27. Multicenter study of hydroxyurea in sickle cell anemia. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia
28. Design of the multicenter study of hydroxyurea in sickle cell anemia
29. Correlation between hypomethylation of DNA and expression of globin genes in Friend erythroleulemia cells
30. First report of reversal of organ dysfunction in sickle cell anemia by the use of hydroxyurea: Splenic regeneration
31. Increased fetal hemoglobin production in patients receiving valproic acid for epilepsy
32. On the induction of fetal hemoglobin by butyrates: In vivo and in vitro studies with sodium butyrate and comparison of combination treatments with 5-AzaC and AraC
33. Alpha-Amino-N-butyric acid stimulates fetal hemoglobin in the adult
34. CpG methyltion remodels chromatin structure in vitro
35. French Study Grp Sickle Cell Dis. Preliminary report of a toxicity study of bydroxyurea in sickle cell disease
36. 5-Azacytidine stimulates fetal hemoglobin synthesis in anemic baboons
37. Hydroxyurea use during pregnancy: A case report in sickle cell disease and review of thc literature
38. Role of erythroid Kruppal-like factor in human γ-to β-globin gene switching
39. Individual variation in the production and survival of F cells in sickle-cell disease
40. Induction of fetal hemoglobin production in subjects with sickle cell anemia by oral sodium phenylbutyrate
41. Increased fetal hemoglobin in patients receiving sodium 4-phenylbutyrate
42. Hydroxyurea induction of hemoglobin F production in sickle cell disease: Relationship between cytotoxicity and F cell production
43. Expression of the sickle-cell gene in Africa
44. On the use of hydroxyurea erythropoietin combination therapy for sickle cell disease
45. The pharmacological manipulation of fetal haemoglobin: Trials using hydroxyurea and recombinant human erythropoietin
46. Blood polymorphonuclear leukocytes from the majority of sickle cell patients in the crisis phase of the disease show enhanced adhesion to vascular endothelium and increased expression of CD64
47. Methylation and gene control
48. Hydroxyurea for treatment of severe sickle cell anemia: A pediatric clinical trial
49. Enhanced fetal hemoglobin production by phenylacetate and 4-phenylbutyrate in erythroid precursors derived from normal donors and patients with sickle cell anemia and β-thalassemia
50. Hydroxyurea increases hemoglobin F levels and improves the effectiveness of erythropoiesis in β-thalassemia hemoglohin E disease
51. Hemoglobin switching in unicellular erythroid culture of sibling erythroid burst-forming units: Kit ligand induces a dose-dependent fetal hemoglobin reactivation potentiated by sodium butyrate
52. Induction of fetal hemoglobin in the presence of increased 3-hydroxyhutyric acid associated with β-ketothiolase deficiency
53. Variegated expression of a globin transgene correlates with chromatin accessibility but not methylation status
54. Sickle reticulocytes adhere to VCAM-1
55. Activation of a chicken embryonic globin gene in adult erythroid cells by 5-azacytidine and sodium butyrate
56. Inhaled nitric oxide augments nitric oxide transport on sickle cell hemoglobin without affecting oxygen affinity
57. 5′-Flanking sequences mediate butyrate stimulation of embryonic globin gene expression in adult erythroid cells
58. Detection of nitrosyl hemoglobin in venous blood in the treatment of sickle cell anemia with hydroxyurea
59. Effects of hydroxyurea administration on the body weight, body composition and exercise performance of patients with sickle-cell anaemia
60. Pharmacologic treatment of thalassemia intermedia with hydroxyurea
61. Acquired DNA mutations associated with in vivo hydroxyurea exposure
62. Combination of hydroxyurea and a modified transfusion regimen in secondary stroke prevention on sickle cell disease
63. The haematology of steady state homozygous sickle cell disease: Frequency distributions variation with age and sex, longitudinal observations
64. Low concentrations of nitric oxide increase oxygen affinity of sickle erythrocytes in vitro and in vivo
65. Erythrocyte adherence to endothelium in sickle-cell anemia. A possible determinant of disease severity
66. Hydroxyurea therapy decreases the in vitro adhesion of sickle erythrocytes to thrombospondin and laminin
67. Sickle erythrocytes adhere to polymorphonuclear neutrophils and activate the neutrophil respiratory burst
68. DNA methylation and gene regulation
69. The safety and efficacy of hydroxyurea in 2 to 5 year old children with sickle cell disease
70. 5-Azacytidine acts directly on both erythroid precursors and progenitors to increase production of fetal hemoglobin
71. Alterations in protein-DNA interactions in the gamma-globin gene promoter in response to butyrate therapy
72. Maximum urine concentrating ability in children with Hb SC disease: Effects of hydroxyurea
73. Clinical and hematologic effects of hydroxyurea in children with sickle cell anemia
74. In vivo production of nitric oxide in rats after administration of hydroxyurea
75. Integrin α 4β1 and glycoprotain IV (CD36) are expressed on circulating reticulocytes in sickle cell anemia
76. Cellular differentiation cytide analogs and DNA methylation
77. Leg ulcer associated with hydroxyurea treatment in a patient with chronic myelogenous leukaemia: Successful treatment with prostaglandin E1 and pentoxifylline
78. Hydroxyurea reacts with sickle cell hemoglobin to form methemoglobin and other minor species
79. Safety of hydroxyurea in children with sickle cell anemia: Results of the HUG-KIDS study, a Phase I/II trial
80. 2-Deoxy 5-azacytidine and fetal hemoglobin induction in sickle cell anemia
81. Effects of sodium butyrate a new pharmacological agent on cells in culture
82. Augmentation of fetal hemoglobin in anemic monkeys by hydroxyurea
83. DNA methylation and globin gene expression in patients treated with 5-azacytidine
84. 5-Azacytidine selectively increases gamma-globin synthesis in a patient with beta+ thalassemia
85. 5-Azacytidine increases γ-globin synthesis and reduces the proportion of dense cells in patients with sickle cell anemia
86. Is treatment with hydroxyurea leukemogenic in patients with essential thrombocythemia? An analysis of three new cases of leukaemic transformation and review of the literature
87. Metabolic persistence of fetal hemoglobin
88. Current status of thalassemia and the sickle cell syndromes in Greece
89. Fetal hemoglobin and F-cell responses to long-term hydroxyurea treatment in young sickle cell patients
90. Induction of γ-globin by histone deacetylase inhibitors
91. Hydroxyurea-induced HbF production in anemic primates: Augmentation by erythropoietin, hematopoietic growth factors, and sodium butyrate
92. Specific DNA methylation sites in the vicinity of the chicken β-globin genes
93. Influence of steel factor on hemoglobin synthesis in sickle cell disease
94. Splenic function in patients with sickle cell disease treated with hydroxyurea
95. Prospective study of splenic hypofunction during therapy with hydroxyurea in patients with sickle cell disease
96. Use of hydroxyurea in patients with sickle cell anemia on chronic transfusion
97. Structural basis for the inhibitory effects of hemoglobin F and hemoglobin A2 on the polymerization of hemoglobin S
98. Hemoglobins of the embryo and fetus and minor hemoglobins of adults
99. Treatment of polycythemia vera: Use of 32P alone or in combination with maintenance therapy using hydroxyurea in 461 patients greater than 65 years of age
100. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
101. Pharmacological manipulation of fetal hemoglobin synthesis in patients with severe beta-thalassemia
102. Painful oral ulcers with hydroxyurea therapy
103. Treatment of thalassaemia major with phenylbutyrate and hydroxyurea
104. Hydroxyurea in children with sickle cell disease: Impact on splenic function and compliance with therapy
105. In vivo search for butyrate responsive sequences using transgenic mice carrying Aγ gene promoter mutants
106. Hydroxyurea induced erythropoietin secretion in sickle cell syndromes may contribute in their HbF increase
107. Hemoglobin F synthesis in vitro: Evidence for control at the level of primitive erythroid stem cells
108. Arabinosylcytosine induces fetal hemoglobin in baboons by perturbing erythroid cell differentiation kinetics
109. Stimulation of fetal hemoglobin synthesis in bone marrow cultures from adult individuals
110. Pharmacokinetics (PK) of hydroxyurea (HU) in children with sickle cell anemia (SCA)
111. Isobutyramide, an orally bioavailable butyrate analogue, stimulates fetal globin gene expression in vitro and in vivo
112. A short-term trial of butyrate to stimulate fetal-globin-gene expression in the β-globin disorders
113. Delay in the fetal globin switch in infants of diabetic mothers
114. Sodium butyrate enhances fetal globin gene expression in erythroid progenitors of patients with Hb SS and beta thalassemia
115. Butyric acid analogues augment γ globin gene expression in neonatal erythroid progenitors
116. Butyrate infusions in the ovine fetus delay the biologic clock for globin gene switching
117. Fetal hemoglobin in starvation ketosis of young women
118. Mortality in sickle cell disease: Life expectancy and risk factors for early death
119. Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia
120. Sparing effect of hemoglobin F and hemoglobin A2 on the polymerization of hemoglobin S at physiologic ligand saturations
121. Two siblings with unusually mild homozygous β-thalassemia: A didactic example of the effect of a nonallelic modifier gene of the expressivity of a monogenic disorder
122. The role of recombinant human erythropoietin in the treatment of thalassemia
123. Sustained increase in haemoglobin and RBC following long-term administration of recombinant human erythropoietin to patiens with homozygous beta-thalassaemia
124. Leukemogenesis of hydroxyurea in the treatment of sickle cell anemia
125. Cutaneous ulcers associated with hydroxyurea (HU) therapy in myeloproliferative disorders
126. Induction of fetal hemoglobin synthesis in children with sickle cell anemia on oral sodium phenylbutyrate
127. Clinical and hematological response to hydroxyurea in a patient with Hb lepore/β-thalassemia
128. Hematologic responses of patients with sickle cell disease to treatment with hydroxyurea
129. Augmentation by erythropoletin of the fetal-hemoglobin response to hydroxyurea in sickle cell disease
130. A bioavailability and pharmacokinetic study of oral and intravenous hydroxyurea
131. Extension of the pilot trial of hydroxyurea (HU) in very young children with sickle cell anemia (SCA)
132. Age and sex effects on hemoglobin F in sickle cell anemia
133. Levels of endothelial, neutrophil and platelet-specific factors in sickle cell anemia patients during hydroxyurea therapy
134. Isobutyramide therapy in patients with sickle cell anemia
135. Nitric oxide generation from hydroxyurea via copper-catalyzed peroxidation and implications for pharmacological actions of hydroxyurea
136. A new genetic variant of beta-thalassaemia
137. Hydroxyurea therapy in children severely affected with sickle cell disease
138. Valproic acid land augmentation of fetal hemoglobin in individuals with and without sickle cell disease
139. Extended therapy with intravenous arginine butyrate in patients with β-hemoglobinopathies
140. Methylation of the minimal promoter of an embryonic globin gene silences transcription in primary erythroid cells
141. Sickle cell disease and metabolic persistence of fetal hemoglobin: Phenotypic modulation by inherited metabolic disease
142. Pattern of methylation of two genes coding for housekeeping functions
143. Management of sickle cell disease
144. Compound heterozygous and other hemoglobinopathies
145. Mortality at 4-5 years: Results from the the multicenter study of hydroxyurea in sickle cell anemia (MSH)
146. Risks and benefits of hydroxyurea (HU) in adult sickle cell anemia. Effects at 6- to 7-years
147. Hydroxyurea (HU) is associated with reduced mottality in adults with sickle cell anemia
148. Concordant HbF response to hydroxyurea (HU) in siblings with sickle cell anemia (HbSS)
149. The multicenter study of hydroxyurea in sickle cell anemia (MSH): Mortality at 5-6 years
150. Fetal hemoglobin in sickle cell anemia: Determinants of response to hydroxyurea
151. Cellular effects of hydroxyurea in Hb SC disease
152. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: High proportion of cases with 17p deletion
153. Decrease of very late activation antigen-4 and CD36 on reticulocytes in sickle cell patients treated with hydroxyurea
154. Thrombospondin mediates adherence of CD36+ sickle reticulocytes to endothelial cells
155. Absence of cross-resistance to the HbF stimulating activities of butyrate & hydroxyurea
156. Progressive pulmonary hypertension and pulmonary insufficiency in sickle cell patients who respond to hydroxyurea
157. α4β1-Integrin expression on sickle reticulocytes: Vascular cell adhesion mulecule-1-dependent binding to endothelium
158. Perturbations in the erythroid marrow progenitor cell pools may play a role in the augmentation of HbF by 5-azacytidine
159. Fetal hemoglobin variations following hydroxyurea treatment in patients with cyanotic congenital heart disease
160. Predicting the effectiveness of hydroxyurea in individual sickle cell anemia patients
161. DNA methylation in the human γδβ-globin locus in erythroid and nonerythroid tissues
162. Stimulation of F-cell production in patients with sickle-cell anemia treated with cytarabine or hydroxyurea
163. Treatment of baboon with vinblastine: Insights into the mechanisms of pharmacologic stimulation of HbF in the adult
164. A cautionary note regarding hydroxyurea in sickle cell disease
165. Clinical and laboratory effects of long-term administration of hydroxyurea to patients with sickle-cell/β-tha assaemia
166. Hydroxyurea therapy for pediatric patients with Hemoglobin SC disease: Laboratory and clinical effects
167. Hydroxyurea: An alternative to transfusion therapy for stroke in sickle cell anemia
168. Hydroxyurea as an alternative to blood transfusions for the prevention of recurrent stroke in children with sickle cell disease
169. Significance of paucity of sickle cells in newborn negro infants
170. Acute leukaemia after hydroxyurea therapy in polycythemia vera and allied disorders: Prospective study of efficacy and leukaemogenicity with therapeutic implications
171. Laboratory profile of sickle cell disease: A cross-sectional analysis
172. Unusually large von Willebrand factor multimers preferentially promote young sickle and nonsickle erythrocyte adhesion to endothelial cells
173. Acute leukemia in a patient with sickle-cell anemia treated with hydroxyurea
174. Nitrosylation of sickle cell hemoglobin by hydroxyurea
175. Cloning and characterization of a potential transcriptional activator of human gamma-globin genes
176. Hydroxyurea: Inhibitory effect on DNA metabolism
177. Hydroxyurea therapy in β-thalassaemia intermedia: Improvement in haematological parameters due to enhanced β-globin synthesis